4-Amino-3-hydroxybenzoic acid

We are 4-Amino-3-hydroxybenzoic acid CAS:4-氨基-3-羟基苯甲酸 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Synonyms:
4-Amino-3-hydroxy benzoic acid
2-hydroxyaniline
2-Amino-5-carboxyphenol
3-hydroxy-4-aminobenzoate
2hdr
2-hydroxy-4-carboxyaniline
3-hydroxy-4-amino-benzoic acid
4-Amino-3-hydroxybenzoic Acid
 
Molecular Formula:  C7H7NO3
Molecular Weight: 153.13500

Appearance and properties: yellow-brown solid
Density: 1.028
Boiling point: 385.7ºC at 760 mmHg
Melting point: 211-215 °C(lit.)
Flash point: 187.1ºC
Refractive index: 1.691
 
Storage conditions: airtight, kept in a cool and dry place.

Items of Analysis Standard of Analysis Test Results
Appearance Yellowish to gray powder Conform
Assay ≥98.0% 99.10%
Single impurity ≤0.5% 0.31%
Solvent residue ≤0.2% 0.02%
Melting point 211-215℃ 211-213℃
Loss on drying ≤0.5%  0.37%
Conclusion Conforms to Factory Standard
 

 
 
 
 

4-Amino-3-hydroxybenzoic acid


Related News: 5-(Trifluoromethyl)indole CAS:100846-24-0 This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician’s Choice plus Best Supportive Care.592-09-6 This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician’s Choice plus Best Supportive Care.38234-21-8 This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician’s Choice plus Best Supportive Care.This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician’s Choice plus Best Supportive Care.

Related Products
Product Name
2-methyl-2-(methylsulfanyl)propanaldoxime View Details
D-Serine methyl ester hydrochloride View Details
9-(4-broMophenyl)-10-(naphthalen-1-yl)anthracene View Details
Methyl hexadecanoate manufacturer 4,5-Diamino-1-(2-Hydroxy)Ethyl Pyrazole Sulfate manufacturer 4-Propylphenylboronic acid manufacturer Ethyl 3-(4-(methylamino)-3-nitro-N-(pyridin-2-yl)benzamido)propanoate manufacturer N-[4-(4-Fluorophenyl)-5-formyl-6-(1-methylethyl)-2-pyrimidinyl]-N-methyl-methanesulfonamide manufacturer